Allison E James, Brandy Sutphin, Patrick Fleming, Donald McCormick, Appathurai Balamurugan
{"title":"Characteristics of E-Cigarette, or Vaping, Product Use-Associated Lung Injury (EVALI) Patients.","authors":"Allison E James, Brandy Sutphin, Patrick Fleming, Donald McCormick, Appathurai Balamurugan","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>During August-December 2019, 23 persons who received a diagnosis of e-cigarette, or vaping, product use-associated lung injury (EVALI) were reported to the Arkansas Department of Health (ADH); none died. Among Arkansas EVALI patients, most were aged <25 years and white; two-thirds were male. Approximately half of Arkansas EVALI patients were admitted to intensive care units. Among 18 patients who were interviewed, 61% reported using both nicotine and tetrahydrocannabinol in an e-cigarette, or vaping, device during the 90 days preceding illness onset. Clinicians should remain vigilant for EVALI and continue to report cases to ADH.</p>","PeriodicalId":75122,"journal":{"name":"The Journal of the Arkansas Medical Society","volume":"117 5","pages":"110-112"},"PeriodicalIF":0.0000,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174092/pdf/nihms-1703187.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of the Arkansas Medical Society","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
During August-December 2019, 23 persons who received a diagnosis of e-cigarette, or vaping, product use-associated lung injury (EVALI) were reported to the Arkansas Department of Health (ADH); none died. Among Arkansas EVALI patients, most were aged <25 years and white; two-thirds were male. Approximately half of Arkansas EVALI patients were admitted to intensive care units. Among 18 patients who were interviewed, 61% reported using both nicotine and tetrahydrocannabinol in an e-cigarette, or vaping, device during the 90 days preceding illness onset. Clinicians should remain vigilant for EVALI and continue to report cases to ADH.